🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 27% of ingredients have research evidence
B Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

1 Teaspoon(s) Serving Size
100 Servings
Fat/Fatty Acid Product Type
27% Evidence Coverage

Supplement Facts — Evidence Check

Calories
40 {Calories}
Calories from Fat
40 {Calories}
Total Fat
4 Gram(s)
Saturated Fat
1 mg
Polyunsaturated Fat
2 Gram(s)
Monounsaturated Fat
1 Gram(s)
Cholesterol
15 mg
Omega Fatty Acids
1500 mg
📊 Market median: 750.0mg (447 products) 📚 388 studies (Tier A: 18, B: 204)
This product: 800mg UL 3000mg
📊 Market median: 750.0mg (447 products) 📚 388 studies (Tier A: 18, B: 204)
This product: 500mg UL 3000mg
📊 Market median: 750.0mg (447 products) 📚 388 studies (Tier A: 18, B: 204)
This product: 200mg UL 3000mg

Other Ingredients

natural Lemon flavor Rosemary extract Ascorbyl Palmitate Tocopherol

Label Claims — Verification

No Claim
All Other (99% of products) Structure/Function (86% of products) Nutrient (79% of products) Qualified Health (13% of products) Approved Health (2% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

Additional Information

Item #: VS-2642 / 1698042

Product Details

DSLD Entry Date 2013-10-25
Product Type Fat/Fatty Acid
Form Liquid
DSLD ID 26980
Data Updated 2026-04-11

Research Evidence

495 Research Sources
56 Avg Quality Score
222 Meta Analysis
104 Clinical Trial
72 Rct
69 Systematic Review
11 Guideline
5 Cochrane Review
5 Regulatory Source
3 Narrative Review
1 Openfda Safety
A Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2018
A Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2020
A Omega-3 fatty acid addition during pregnancy
Meta Analysis The Cochrane database of systematic reviews 2018
A Omega-3 fatty acids for depression in adults
Systematic Review The Cochrane database of systematic reviews 2021
A Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2018
A Non-immunosuppressive treatment for IgA nephropathy
Meta Analysis The Cochrane database of systematic reviews 2024
A Omega-3 fatty acid supplementation for depression in children and adolescents
Meta Analysis The Cochrane database of systematic reviews 2024
A Interventions for fatigue and weight loss in adults with advanced progressive illness
Meta Analysis The Cochrane database of systematic reviews 2012
A Motor control exercise for chronic non-specific low-back pain
Meta Analysis The Cochrane database of systematic reviews 2016
A Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2018
View all evidence for Omega 3 →

Compare Similar Products

View all Omega 3 products →